GERNGERON CORP

Nasdaq geron.com


$ 4.65 $ 0.09 (1.97 %)    

Tuesday, 27-Aug-2024 10:48:35 EDT
QQQ $ 476.92 $ 2.46 (0.52 %)
DIA $ 412.59 $ 0.33 (0.08 %)
SPY $ 561.49 $ 2.35 (0.42 %)
TLT $ 97.61 $ 0.04 (0.04 %)
GLD $ 232.67 $ 0.99 (0.43 %)
$ 4.56
$ 4.56
$ 4.64 x 2,000
$ 4.65 x 2,000
$ 4.51 - $ 4.66
$ 1.64 - $ 5.34
4,725,108
na
2.75B
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-16-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-10-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-11-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-28-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 03-07-2019 12-31-2018 10-K
24 11-01-2018 09-30-2018 10-Q
25 07-31-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-16-2018 12-31-2017 10-K
28 11-01-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-01-2017 12-31-2016 10-K
32 11-03-2016 09-30-2016 10-Q
33 08-03-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 03-10-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 08-05-2015 06-30-2015 10-Q
38 05-07-2015 03-31-2015 10-Q
39 03-11-2015 12-31-2014 10-K
40 11-05-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-geron-maintains-6-price-target

Needham analyst Gil Blum reiterates Geron (NASDAQ:GERN) with a Buy and maintains $6 price target.

 geron-q2-2024-gaap-eps-010-inline-sales-780000k-beat-274857k-estimate

Geron (NASDAQ:GERN) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. The company repor...

 needham-reiterates-buy-on-geron-maintains-6-price-target

Needham analyst Gil Blum reiterates Geron (NASDAQ:GERN) with a Buy and maintains $6 price target.

 barclays-initiates-coverage-on-geron-with-overweight-rating-announces-price-target-of-9

Barclays analyst Carter Gould initiates coverage on Geron (NASDAQ:GERN) with a Overweight rating and announces Price Target ...

 barclays-initiates-coverage-on-geron-with-overweight-rating-announces-price-target-of-9

Barclays initiates coverage on Geron (NASDAQ:GERN) with a Overweight rating and announces Price Target of $9.

 stifel-maintains-buy-on-geron-raises-price-target-to-7

Stifel analyst Stephen Willey maintains Geron (NASDAQ:GERN) with a Buy and raises the price target from $6 to $7.

 fda-approves-gerons-first-commercial-drug-competes-with-bristol-myers-squibbs-blood-cancer-drug

FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION